- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03449888
Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome (ArmCrank)
Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome Prediction
Study Overview
Status
Detailed Description
Note: Recruitment is temporarily suspended because of VA-ORD moratorium due to Covid-19 pandemic. 04/01/2020
Treadmill exercise capacity and other physiologic responses to leg exercise are powerful predictors of mortality and provide important clinical and diagnostic information. However, many Veterans cannot perform treadmill exercise because of lower extremity or other disabilities. For many years, pharmacologic myocardial perfusion imaging (MPI) has been the standard of care for their evaluation but fails to provide powerful prognostic and clinically relevant information of exercise testing, requires exposure to ionizing radiation, and is several times more expensive than exercise electrocardiography (ECG). With a recently completed Merit Review award, we obtained substantial retrospective observational evidence that arm exercise ECG stress testing scores are at least equivalent to pharmacologic MPI for robust prediction of mortality and other measures of clinical outcome in Veterans who cannot perform leg exercise. Major hypotheses for the current proposal are: 1) arm exercise ECG stress testing scores or best fit models without or with coronary artery calcium scoring (-/+ CACS) are non-inferior to the Duke Treadmill Score -/+ CACS, best fit model treadmill ECG and regadenoson (r) MPI stress testing, all performed in the same Veterans in randomized order, as an initial evaluation for obstructive coronary artery disease (oCAD), and 2) arm exercise ECG stress testing scores or best fit models -/+ CACS are non-inferior to the Duke Treadmill Score -/+ CACS, best fit model treadmill ECG and rMPI stress testing in the same Veterans for predicting the primary clinical endpoint (composite of cardiovascular (CV) mortality, myocardial infarction, or 90-day post-stress test coronary revascularization) and secondary clinical endpoints of all-cause mortality and CV mortality. Our specific aim for all Veterans referred to the St. Louis Veterans Administration (VA) stress testing laboratory and are without exclusions for exercise or regadenoson stress testing or cardiac computed tomographic angiography (CTA), is to perform a single site prospective clinical trial comparing arm exercise ECG stress test scores and best models -/+ CACS with the Duke Treadmill Score -/+ CACS if able to perform treadmill exercise, and best fit treadmill ECG and rMPI models, all performed in the same Veterans, for identification of the diagnostic endpoint of oCAD, defined as a severely ( 70%) occluded epicardial, graft, or 50% left main coronary artery lumen, determined by cardiac CTA or invasive coronary arteriography, and prediction of the primary and secondary clinical endpoints described above. The arm exercise scoring system to be evaluated incorporates the variables arm exercise capacity in resting metabolic equivalents, 1-minute heart rate recovery and arm exercise-induced ST depression of 1 mm or greater. Regadenoson MPI variables to be evaluated include an abnormal MPI study and best fit models of summed stress and difference scores, transient ischemic dilatation, gated left ventricular ejection fraction, and the heart rate response. We plan to enroll 75 Veterans per year for 4 years and follow the entire cohort for an additional year. Statistical analyses will be performed with SAS using univariate and multivariate logistic and Cox regression models. We will evaluate non-inferiority of arm exercise scores -/+ CACS for their association with oCAD and prediction of clinical endpoints with a non-inferiority margin of 0.05. A long term goal is to develop a multi-site prospective randomized VA Cooperative Study to assess generalizability of arm exercise ECG stress testing -/+ CACS for diagnostic and prognostic evaluation in the VA and United States healthcare systems.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63106
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any veteran referred to the St. Louis VA Healthcare System stress testing laboratory for a cardiac stress test
Exclusion Criteria:
- Contra-indications to stress testing such as acute coronary syndrome, uncompensated heart failure, or unstable cardiac dysrhythmias Inability to perform arm exercise stress testing
- Contra-indications to regadenoson stress testing such as significant reversible airway disease, heart block, or low blood pressure
- An abnormal baseline ECG (e.g. left bundle branch block, widespread ST segment depression of at least 1 mm, ventricular paced rhythm) that precludes interpretation of the stress ECG
- Contra-indications to cardiac computed tomographic angiography (CTA) such as contrast allergies and renal dysfunction (glomerular filtration rate < 30 ml/min)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
St. Louis VA Healthcare System stress testing referrals
St. Louis VA Healthcare System cardiac stress testing laboratory referrals who are eligible and willing to complete an arm exercise ECG stress test, a treadmill ECG stress test if able, a regadenoson myocardial perfusion imaging stress test, and a coronary artery calcium score and cardiac computed tomographic angiography evaluation within 60 days if not referred for invasive coronary arteriography.
|
Best fit model of pharmacologic myocardial perfusion imaging data, including summed stress and difference scores, gated left ventricular ejection fraction, transient ischemic dilatation, and heart rate response to regadenoson data.
Other Names:
Published arm exercise score and best fit model of arm exercise ECG stress testing data.
Other Names:
Duke Treadmill Score and best fit model of treadmill exercise ECG stress testing data.
Other Names:
Coronary artery calcium score by Agatston criteria and severe obstructive coronary artery disease > 70% by cardiac computed tomographic angiography or invasive coronary arteriography.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite of cardiovascular mortality, myocardial infarction, and 90-day post-stress test coronary artery revascularization
Time Frame: 5 years
|
Death from a cardiovascular cause, occurrence of myocardial infarction, and 90-day post-stress test coronary artery revascularization by any technique determined from VA, National Death Index, Missouri Health and Human Services, and non-VA medical records, and patient follow-up information.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: 5 years
|
Death from any cause determined from VA, Social Security, and National Death Index records and patient follow-up information.
|
5 years
|
Cardiovascular mortality
Time Frame: 5 years
|
Death from a cardiovascular cause determined from VA, Missouri Health and Human Services, and National Death Index records and patient follow-up information.
|
5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Obstructive coronary artery disease
Time Frame: 5 years
|
Severely (at least 70%) or completely occluded epicardial coronary arteries or grafts determined by cardiac computed tomographic angiography or invasive coronary arteriography
|
5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Wade H. Martin, MD, St. Louis VA Medical Center John Cochran Division, St. Louis, MO
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Purinergic Agents
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Purinergic P1 Receptor Agonists
- Purinergic Agonists
- Adenosine A2 Receptor Agonists
- Calcium
- Calcium, Dietary
- Regadenoson
Other Study ID Numbers
- CARA-008-17F
- 1 101 CX001345-01A3 (OTHER: VA St. Louis Health Care System)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Regadenoson myocardial perfusion imaging stress test
-
Walter Reed Army Medical CenterUnknownCoronary Artery Disease | Chest Pain | Coronary Atherosclerosis | Stress TestingUnited States
-
Cedars-Sinai Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCoronary Artery Disease | Coronary Microvascular DiseaseUnited States
-
Montefiore Medical CenterAlbert Einstein College of Medicine; American Heart AssociationCompletedCoronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Unstable AnginaUnited States
-
Montefiore Medical CenterAlbert Einstein College of MedicineTerminatedCoronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Unstable AnginaUnited States
-
Hartford HospitalBracco Diagnostics, IncCompletedMyocardial Ischemia | Coronary Artery Disease | Heart DiseaseUnited States
-
Sir Mortimer B. Davis - Jewish General HospitalUnknownCoronary Artery Disease | Coronary Heart Disease
-
American College of RadiologyTerminatedCoronary Artery Disease | Chest Pain | Stable Angina Pectoris, CCS Class I to III | Angina EquivalentUnited States
-
National Heart Centre SingaporeNational Medical Research Council (NMRC), SingaporeRecruitingCoronary Artery Disease | Diabetes MellitusSingapore
-
Aspire FoundationBlue Cross Blue Shield; Saint Luke's Cardiovascular Consultants; Cardiovascular... and other collaboratorsCompletedCoronary Artery DiseaseUnited States
-
St. Louis UniversityAstellas Pharma US, Inc.WithdrawnCoronary Artery DiseaseUnited States